2024-03-31 02:10:00 ET
Summary
- Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs.
- Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg.
- Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.
- While Viking's data is immature and based on small patients samples, however, Lilly and Novo's vast experience and established infrastructure mean they remain well ahead of the competition.
- In fact, Lilly and Novo's next-generation drug looks better than any other companies, and as crazy as it may sound, it may be that a trillion dollar market cap valuation beckons.
Investment Overview- Background To Stunning Rise Of GLP-1 Analogue Drug Class
Doubtless, readers will be familiar with the Wegovy / Zepbound, Ozempic / Mounjaro, tirzepatide / semaglutide "miracle" weight loss story by now - but to recap:
Semaglutide is a glucagon-like peptide-1 receptor agonist, or "GLP-1" agonist / analogue developed by Danish Pharma Novo Nordisk ( NVO ). These types of drugs have been used for many years to treat type 2 diabetes, as they prompt the body to produce more insulin....
Read the full article on Seeking Alpha
For further details see:
Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data